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IMMUNE RESPONSES TO A LIVE VIRUS VACCINE CANDIDATE 
AND PROTECTION AGAINST PSEUDORABIES VIRUS INFECTION 
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A comparative study of three Malaysian pseudorabies VIruS (PrV) 
isolates, one Malaysian PrY strain and one American reference PrY was carried 
out using restriction endonucleases. Variations were observed among these 
viruses when their DNAs were digested with only Kpn I and BamH I enzymes. 
The Malaysian strain (PrV-mA1p) showed restriction pattern which was different 
from its parental virus. An obvious differences were observed between the 
reference virus and the Malaysian PrVs. When the SDS-PAGE technique was 
employed, no significant variations in protein profiles of the Pr V s but variations 
in their immunogenic proteins were observed when they were reacted against 
homologous and heterologous antisera in Western blotting. The viruses were 
suggested to belong to the same serologic sub-type using SNT and ELISA tests. 
Experiments in mice demonstrated that all the viruses were pathogenic to 
various extents while PrV-mAlp was found to be non-pathogenic even when 
mice were infected with 108 p.f.u. The study showed that 100% protection was 
obtained following immunization of mice with at least 105 p.f.u. However, the 
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protection level was highly dose and route of immunization dependent. Antibody 
(Ab) responses to PrY -mAl p were correlated with the protection levels obtained 
and demonstrated to persist in mouse serum for five consecutive months. 
Low levels of neutralizing Ab (N-Ab) were detected in mice following 
immunization with PrV-mAl p  depending on the dose and route of inoculation. 
They were correlated with the protection levels but not with the ELISA Ab titres. 
Higher DTH responses were observed in mice immunized with PrV-mAl p  
especially via intranasal route (i.n.). A second dose of immunization slightly 
increased the DTH response. A significant (p<0.05) increase of PrV-mAl p  
growth was observed in mice tissues treated with immunosuppressive agents. 
However, the highest virus titres were detected in cyclophosphamide (CPS)­
treated mice followed by dexamethasone (DXM)- and flumethasone (FLM)­
treated mice. A significant (p<0.0 l )  decline in Ab titres following treatment of 
mice with all the drugs was noted. However, the highest decline was observed in 
CPS-treated mice. PrY -rnA 1 p was reactivated in low titres from latently infected 
nervous tissues of mice using CPS and DXM but not from respiratory tissues. 
Increases in the protection levels and Ab responses were observed in mice 
immunized with the algammulin-adjuvanated PrV-mAlp.  PrV-mAl p  was also 
found to be non-pathogenic for swine following inoculation of piglets with up to 
1 08 p.f.u. but displayed high levels of immunogenicity in piglets, hence the virus 
was highly suitable to be proposed as a live virus vaccine against PrY infection. 
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GERAKBALAS IMUN TERHADAP CALON V AKSIN VIRUS HID UP 
DAN PERLINDUNGAN TERHADAP JANGKITAN VIRUS 
PSEUDORABIES 
Oleh 
ABDEL-WAHID SAEED ALI BABIKER 
Desember 1999 
Pengerusi: Mohd. Azmi Mohd. Lila, Ph.D. 
Fakulti: Perubatan Veterinar 
Suatu kaj ian banding an terhadap pencilan virus pseudorabies Malaysia 
(PrV), satu strain PrY Malaysia dan satu PrY rujukan Amerika telah dijalankan 
mengguna endonuklease pengehadan. Perbezaan telah dicerap di kalangan virus 
ini apabila DNAnya dicernakan dengan enzim Kpn I dan BamH 1 sahaja. Strain 
Malaysia (PrV-mAlp) menunjukkan pola pengehadan yang berbeza daripada 
virus induknya. Suatu perberzaan yang nyata dicerapkan di antara virus rujukan 
dan PrY Malaysia. Apabila teknik SDS-PAGE digunakan, tiada perbezaan tererti 
didapati dalam profil protein PrY tetapi perbezaan dalam protein imunogen telah 
dicerapkan apabila ianya ditindakkan dengan antiserum homologus dan 
heterologus dalam sap Western. Dengan mengguna ujian SNT dan ELISA, virus-
virus ini disarankan adalah daripada sub-tip serologi yang sarna. 
Ujikaji pada mencit menunjukkan yang kesemua virus ini patogen pada 
tahap yang berbeza-beza, sambil PrV-mAlp pula didapati bukan patogen 
walaupun mencit ini telah dijangkitkan dengan 108 p.f.u. Kaj ian ini menunjukkan 
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yang perlindungan 100% diperolehi berikutan penglmunan mencit dengan 
sekurang-kurangnya 105 p.f.u. Bagaimanapun. aras perlindungan ini paling 
bersandarkan dos dan cara pengimunan. Gerak balas antibodi (Ab) terhadap PrV­
rnA 1 p berkorelasikan dengan aras perlindungan dan ini telah ditunjuk berterusan 
dalam serum mencit selama 5 bulan. 
Aras Ab peneutralan (N-Ab) yang rendah telah dikes an dalam mencit 
berikutan pengimunan dengan PrV-mAlp, iaitu bergantung kepada dos dan cara 
penginokulatan. lni berkorelasi dengan aras perlindungan tetapi bukan dengan 
titer Ab ELISA. Gerak balas DTH dicerap lebih tinggi dalam mencit terimun 
dengan PrV-mAlp, khususnya dengan cara intranasum (i.n.). Satu dos 
pengimunan kedua meningkatkan sedikit gerak balas DTH In!. Peningkatan 
tererti (p<0.05) pertumbuhan PrY -mAl p dicerapkan dalam tisu mencit yang 
diperlakukan dengan agen imunotindas. Bagaimanapun, titer virus paling tinggi 
dikesan dalam mencit terperlaku siklofosfamida (CPS) diikuti dengan mencit 
terperlaku deksametason (DXM) dan flumetason (FLM). Penurunan tererti 
(P<O.Ol) dalam titer Ab berikutan perlakuan men cit dengan kesemua drug ini 
telah dilihat. Bagaimanapun, penurunan paling besar dicerapkan dalam mencit 
terperlaku CPS. PrV-mAlp telah diaktif semula sekadar titer rendah daripada tisu 
saraf men cit terjangkit pendam mengguna CPS dan DXM, tetapi perkara ini tidak 
berlaku daripada tisu pemafasan. 
Peningkatan dalam aras perlindungan dan gerak balas Ab dicerapkan 
dalam mencit yang terimun dengan PrV-mAlp teradjuvan algamulin. PrV-mAl p  
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Juga didapati bukan patogen untuk babi berikutan penginokulatan anaknya 
dengan setinggi 108 pJ.u., tetapi telah menunjukkan keimunogenan aras tinggi 
dalam anak babi tersebut, dan justeru itu virus ini adalah paling sesuai disarankan 




Pseudorabies virus (PrV) is a neurotropic herpesvirus that causes 
pseudorabies in domestic and wild animals (Gustafson, 1 986; Pensaert and 
Kluge, 1 989). The first description of PrY infectivity was made in 1 902 by 
Aujeszky, a Hungarian scientist (Aujeszky, 1 902) hence the name Auj eszky's 
disease. Pigs are relatively resistant to PrY and are the natural host. Other 
secondary hosts include cattle, sheep, dogs and cats (Pensaert and Kluge, 1 989). 
Laboratory animals such as rabbits and mice can be infected (Nash et ai., 1 980). 
Aujeszky's  disease is characterized by inflammation of the respiratory 
tract and a severe encephalomyelitis (Crandell, 1982; E ich, 1 983) . The common 
route of PrY entry is the nasopharyngeal region. The virus is able to replicate in 
cells of nasal and pharyngeal mucosa (Pol et ai., 1 989). After the infection of the 
peripheral neural cells, the virus is transported to the central nervous system, 
where it causes a severe encephalitis which is fatal in young pigs (Baskerville et 
ai., 1 973; Dow and McFerran, 1 962). Clinical signs of pseudorabies depend on 
the virulence of the virus strain, the infective dose and the age of the animal 
affected. Infection in older pigs results in respiratory and reproductive disorders. 
Infection with mild strains of the virus results in an inapparent infection (Kluge et 
ai., 1 992). 
